Engineered Extracellular Vesicles for Targeted Tissue Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic extracellular vesicles (EVs) lack specificity and efficiency in targeting damaged or diseased tissues, requiring local delivery and altering vesicle-producing cells, which limits their application and effectiveness.
Innovation Solution
Engineered EVs equipped with a modular membrane cloaking platform, featuring a lipid anchor moiety, targeting moiety, and reporter moiety, allowing for systemic delivery and enhanced targeting and uptake by specific cells without altering the producing cells, using a functionalizing unit that includes a coupling moiety and spacer to improve tethering and orientation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If local delivery is used to ensure specific targeting of therapeutic EVs to diseased tissue, then targeting specificity is improved, but device complexity and treatment complexity increase
Solution Approach 1:
The patent applies local quality by modifying only the surface properties of EVs at the molecular level through attachment of targeting moieties (such as antibodies, peptides, or ligands) that specifically recognize diseased tissue markers. This localized molecular modification enables systemic EVs to achieve site-specific delivery without requiring complex delivery device infrastructure, thus improving targeting specificity while maintaining simple administration procedures.
2Reliability
If vesicle-producing cells are altered to enhance EV therapeutic function, then therapeutic efficacy is improved, but ease of manufacture and safety increase complexity
Solution Approach 1:
The patent segments the therapeutic system into two independent components: (1) EVs produced by standard, unmodified cells that can be manufactured using existing protocols, and (2) targeting moieties that are attached to the EV surface after production. This segmentation allows the EV production process to remain simple and well-established while the therapeutic functionality is enhanced through modular surface attachment, avoiding the complexities of genetically modifying vesicle-producing cells.
3Productivity
If EVs are engineered with targeting moieties to achieve systemic delivery, then productivity and treatment efficiency are improved, but device complexity increases
Solution Approach 1:
The patent extracts the targeting function from the EV production process and implements it as a separate, post-production modification step. Targeting moieties are attached to purified EVs using established biochemical conjugation methods, allowing the EVs to be produced using standard protocols and then functionalized for systemic delivery. This extraction approach enables treatment efficiency improvement through systemic administration without requiring complex integrated production-delivery systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables specific and efficient delivery of therapeutic cargo to target cells and tissues, allowing for systemic administration and improved residency time, enhancing therapeutic efficacy and reducing the need for local delivery and cell alteration.
Implementation Method 1
the anchor moiety comprises a hydrophobic moiety configured to insert (i.e., be buried or embedded) at least partially in a EV membrane
Data Source
AI summary
Several embodiments relate to engineered extracellular vesicles (EVs) using the membrane cloaking platform technology described herein, the cloaking imparting to the EVs enhanced delivery to tissues of interest, such as damaged or dysfunctional tissue. Several embodiments relate to engineering exosomes derived from cardiosphere-derived cells (CDCs) using the membrane cloaking platform technology described herein to confer enhanced tissue homing specificities, thereby leading to repair and regeneration at sites of injury. Uses of engineered EV compositions to treat diseases are also provided for in several embodiments.